Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele

Articles

Emerging Strategies in the Management of Relapsed/Refractory CLL

August 30th 2021

Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.

Therapeutic Sequencing Strategies in Relapsed/Refractory CLL

August 30th 2021

Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.

Key Clinical Data in Relapsed/Refractory CLL

August 30th 2021

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

Frontline Therapy for CLL: Emerging Agents and Approaches

August 23rd 2021

Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.

Which Path to Take in Frontline Therapy for CLL?

August 23rd 2021

Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.

Frontline Targeted Therapy in CLL: Tolerability and Toxicity Management

August 16th 2021

A comprehensive breakdown of the tolerability of frontline targeted therapies used to manage chronic lymphocytic leukemia and toxicity management.

Optimizing the Frontline Management of High-Risk CLL

August 16th 2021

After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.

Key Clinical Data for Frontline Targeted Therapy in CLL

August 9th 2021

Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.

Global Approaches to the Frontline Management of CLL

August 9th 2021

Considering a patient’s age, as well as their deletion 17p and IgHV status, experts from around the world share their approach to the frontline management of CLL.

Frontline Therapy for Patients With CLL: Testing and Risk Classification

July 30th 2021

A review of how frontline therapy selection for patients with CLL is informed by molecular testing, staging, and risk stratification amidst a multitude of other disease factors.

Impact of Targeted Therapy in CLL

July 30th 2021

Expert insight on the impact that targeted therapies have had on the frontline treatment landscape of chronic lymphocytic leukemia.

Dr. Ghia on Key Findings From the CAPTIVATE Trial in CLL

July 19th 2021

Paolo Ghia, MD, PhD, discusses key findings from the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Novel Treatment Combinations in Chronic Lymphocytic Leukemia

February 24th 2021

Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.

The Future of Chronic Lymphocytic Leukemia Treatment

February 24th 2021

Dr Ghia discusses emerging treatment strategies, including some promising clinical trials in chronic lymphocytic leukemia.

Treatment Sequencing in Chronic Lymphocytic Leukemia

February 24th 2021

Experts provide an in-depth look at their approach in sequencing treatment in chronic lymphocytic leukemia.

Treatment Options in Relapsed/Refractory Chronic Lymphocytic Leukemia

February 17th 2021

Experts discuss second-line treatment options in relapsed/refractory chronic lymphocytic leukemia, including a discussion on the MURANO trial.

Chronic Lymphocytic Leukemia Treatment Considerations 

February 17th 2021

Dr Brown and Dr Stilgenbauer provide advice for community-based oncologists treating chronic lymphocytic leukemia.

Role of Venetoclax in Chronic Lymphocytic Leukemia

February 10th 2021

Experts comment on the use of venetoclax-based therapy in treating chronic lymphocytic leukemia.

A Look at the ECOG 1912 and iLLUMINATE Trials

February 10th 2021

Experts Dr Stilgenbauer and Dr Ghia highlight and comment on the ECOG 1912 and iLLUMINATE trials.

A Look at the ELEVATE-TN and ASCEND Trials

February 3rd 2021

Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.